Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, is set to engage in a fireside chat and individual meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York. The event, which will feature Medicenna’s President and CEO Dr. Fahar Merchant, highlights the company’s advancements in developing novel immunotherapies for cancer and other diseases.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
